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Oxygen Levels in Normal and Previously Irradiated
Human Skin as Assessed by EF5 Binding
Sydney M. Evans1, Amy E. Schrlau1, Ara A. Chalian2, Paul Zhang3 and Cameron J. Koch1
The oxygen status of skin is a controversial topic. Skin is radiosensitive, suggesting it is well-oxygenated.
However, it can be further sensitized with nitroimidazole drugs, implying that it is partially hypoxic. Skin oxygen
levels are difficult to measure with either electrodes or the hypoxia-monitoring agent 3H-misonidazole. For the
latter, binding has previously been reported to be high in murine skin, but this could be attributed to either
non-oxygen-dependent variations in nitroreductase activity, drug metabolism, and/or actual oxygen gradients.
We obtained tumor and skin from patients given EF5, a 2-nitroimidazole tissue hypoxia monitor. We performed
immunohistochemical studies using highly specific monoclonal antibodies for the hypoxia-dependent
production of EF5 tissue adducts. Some tissue sections were counterstained using either Ki67 for proliferation
or CD31 for vessels. We found that the human dermis is well-oxygenated, the epidermis is modestly hypoxic
and portions of some sebaceous glands and hair follicles are moderately to severely hypoxic. Normal and
irradiated skin had similar oxygenation patterns. Control studies demonstrated that these observations are not
due to tissue variations in nitroreductase activity. The importance of the highly heterogeneous distribution of
oxygen in skin requires further study, but recent investigations suggest that skin hypoxia may have important
clinical ramifications including mediating cellular transformation.
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INTRODUCTION
The oxygen level in human skin is of considerable interest to
scientists and physicians in a diverse range of fields.
Anesthesiologists are interested in skin oxygenation as a
monitor of systemic oxygenation. Wound healing or its
absence is known to be affected by tissue oxygenation (Hunt
et al., 2004) and this is of concern to surgeons. Radiation
oncologists have long known that tissue oxygenation affects
the extent of radiation damage; the skin overlying irradiated
volumes is at substantial risk for complications during
radiation treatment of superficial tumors, for example breast
cancer. Acute radiation side effects include erythema and
desquamation; hair loss occurs during or shortly after therapy.
Late radiation effects include fibrosis, telangiectasia, and
secondary malignancies. The etiology of the late radiation
effects is not well defined, especially related to oxygen
dependence. However, there are data to suggest that long-
term production of reactive oxygen species within the
irradiated site may be important (Moeller et al., 2004). The
efficacy of other cancer treatment modalities such as
chemotherapy and photodynamic therapy is also known to
be modified by tissue oxygenation (Yamagata et al., 1992;
Busch et al., 2002).
There have been numerous oxygen partial pressure (pO2)
studies of skin in animal models, particularly rodents and
pigs. However, the direct measurement of pO2 in unper-
turbed human skin has been limited by the lack of
appropriate methodology. Electrode and other studies have
emphasized the pO2 in wounded skin and confirmed the
presence of hypoxia in this situation (Koch et al., 1997; Hunt
et al., 2004). Needle electrode measurements in normal skin
are difficult because of the skin’s highly heterogeneous
composition, its thinness in mice, and its toughness in all
mammals. Indirect information on the pO2 of human skin
comes from its response during radiation therapy. The skin
readily manifests acute radiation damage, inferring that the
proliferating components of the skin are well-oxygenated.
This is also true for hair production and growth, as hair
regrowth is limited following radiation treatment. Extensive
studies by Cobb et al. have documented the uptake of the
prototypic metabolic hypoxia detector 3H-misonidazole in
epidermis and various appendages of rodent skin (Cobb and
Nolan, 1989; Cobb et al., 1989, 1990b). However, the
conclusion reached in these studies was that this and similar
binding in other ‘‘aerobic’’ rodent tissues was artifactual due
to high nitroreductase activity (Cobb et al., 1990c). In
contrast, in vivo studies from other laboratories showed that
high misonidazole binding in esophagus could be inhibited
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by 95% oxygen breathing (Parliament et al., 1992). More
recently, pO2 values of o5 mm Hg have been recorded
in mouse dermis using electron paramagnetic resonance
techniques (Krzic et al., 2001). Thus, the question of the
actual pO2 of skin remains unresolved for both animals
and humans.
EF5 is a 2-nitroimidazole drug that was specifically
designed to monitor tissue hypoxia. It has been validated
for quantitative studies of both neoplastic and non-neoplastic
tissue pO2 in humans and in animal models (Koch et al.,
1995, 2001; Evans et al., 1996, 2004b, 2006; Bergeron et al.,
1999; Koch, 2001). Herein we present data based on EF5
binding as a measure of tissue oxygenation in irradiated and
untreated human skin. Our findings support the extensive
literature on the radiation sensitivity of the skin because we
find that the majority of the skin, that is, the dermis is oxic.
However, EF5 binding is present to varying degrees in human
epidermis and other skin appendages, including portions of
some hair follicles and sebaceous glands. In order to
determine whether this heterogeneity was oxygen dependent
versus an artifact of nitroreductase activity or nonspecific
binding, we performed control studies to assess the maximum
tissue binding under conditions of severe oxygen deprivation.
These data were obtained by incubating small tissue cubes
under 0.02% oxygen with EF3, a sister compound of EF5. This
procedure is called the ‘‘cube reference binding’’ (CRB) study
(Koch, 2001; Evans et al., 2004b). We hypothesize that all skin
appendages in a given patient will bind EF3 equally under the
CRB condition and, therefore, any variations of binding in
vivo would reflect true oxygen differences. The resultant data
are consistent with the conclusion that gradients of EF5
binding result from gradients in oxygen tension rather than
variations in nitroreductase activity. However, the latter
contributes substantially to patient-to-patient variability in
absolute binding and, therefore, must be taken into account
in order to obtain a reasonable estimate of actual tissue pO2.
RESULTS
Skin and tumor tissues from 19 patients were assessed.
Seventeen patients were receiving surgery for head and neck
cancer and two were being treated for extremity sarcoma
(Table 1). Ten patients had received radiation therapy
preceding the surgery at which the tumor and skin tissue
were removed. Skin from two patients who did not receive
EF5 was available for control studies of CRB (see below for
methodological and analytic methods).
Table 1. Patient information
PT ID no. Sex Age (years) Race
Previous radiation
therapy Months1 Tumor site Skin type studied
66 M 47 C Yes 3 H&N Normal and XRT
67 M 62 C No 0 H&N Normal
73 M 65 C Yes 7.5 H&N XRT only
75 M 48 C Yes 24 H&N XRT only
79 F 60 C Yes 10 H&N Normal and XRT
80 M 45 C No 0 H&N Normal
81 M 71 C No 0 H&N Normal
83 M 70 C No 0 H&N Normal
85 M 57 C No 0 H&N Normal
91 M 63 C Yes 3 Sarc XRT only
92 M 66 A Yes 1 Sarc XRT only
93 M 63 C Yes 4 H&N Normal and XRT
94 M 60 C Yes 8.5 H&N Normal and XRT
95 F 59 C Yes 9 H&N XRT only
97 M 74 C No 0 H&N Normal
98 M 64 C Yes 18 H&N XRT only
102 M 69 C No 0 H&N Normal
103 F 62 C No 0 H&N Normal
104 M 68 C No 0 H&N Normal
1052 M 65 C — — — —
1062 F 54 C — — — —
A, Asian; C, Caucasian; H&N, head and neck cancers; Sarc, sarcoma; XRT, radiation therapy.
1From end of XRT to biopsy.
2CRB studies only.
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In situ EF5 binding
Skin is a very complex tissue (Figure 1a). Cell density and
type vary dramatically between the epidermis, dermis, and
the various skin appendages. The typical pattern of in situ EF5
binding seen for normal skin (Figures 1 and 2) includes a
layer of epithelial cells within the superficial epidermis with
moderate EF5 binding. The binding gradient was substantial
with the highest binding below the skin surface in the stratum
granulosum. Only viable cells containing a nucleus bound
EF5, so binding was absent from the metabolically inactive
cells in the stratum corneum and lucidum. Variable binding
was also seen in portions of some sebaceous glands and in an
annular region surrounding the shafts of some portions of
some hair follicles. It is not possible to depict the large range
of EF5 binding in a simple black and white image. Therefore,
the rectangular insets in Figure 2a illustrate a five-fold
electronically enhanced signal in the epidermis and a
relatively low-binding hair follicle. Very little EF5 binding
was seen in the dermis and portions of many skin append-
ages. Similar in situ binding patterns were observed in
irradiated skin (Figure 2c and d).
A summary of the absolute fluorescence intensities for the
in situ binding of skin samples from all patients indicated very
substantial inter- and intra-patient heterogeneity (Table 2a).
However, consistent patterns did emerge (Figures 1 and 2).
For example, binding in the dermis was always much lower
than that of the other skin appendages (epidermis, glands,
hair follicles). Substantial variation occurred in these three
substructures, even within an individual patient’s tissue.
Thus, not all sebaceous glands and hair follicles contained
high binding. Even in samples where there was very bright
binding around some hair shafts, large gradients of binding
away from the hair shaft or sebaceous glands were observed.
Control studies including CRB
Various control studies were performed in order to deter-
mine whether the variations in EF5 binding (Figures 1 and 2,
Table 2a) reflected variations in tissue pO2 versus non-
oxygen dependent binding artifacts. The etiology of such
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Figure 1. The complexity of skin and variations in cell density are
demonstrated in these images of normal human skin. (a) Stained with
hematoxylin and eosin, (b) counterstained with Hoechst 33342 to demon-
strate the location of nuclei, and (c) the EF5 binding patterns (bar¼ 0.25 mm).
Examples of hair follicle (H), sebaceous gland (S), dermis (D), and epidermis
(E) are identified in the hematoxalin and eosin image.
a b
c d
Figure 2. EF5 binding in irradiated and normal skin. (a, b) EF5 binding in nonirradiated and (c, d) irradiated skin. Bar¼1.0 mm. Panels a and c show the
patterns of EF5 binding and Panels b and d show the patterns of nuclei, based on Hoescht 33342 counterstaining. In both normal and irradiated skin, EF5 binding
in dermis5epidermisosebaceous glandsEhair follicles. However, high binding is only found in some hair follicles and sebaceous glands, or in portions
thereof. The fluorescence intensities in the rectangular insets of (a) have been electronically increased by a factor of 5 to show details of the tissue (vertical
arrows). In the upper electronically enhanced rectangle, the contrast between epidermis and dermis is quite striking. Note that the off-tissue intensity is still lower
than the lowest values of the dermis. Despite the five-fold fluorescence enhancement, the cells surrounding the hair shaft depicted in the lower rectangle
are at much lower binding levels than those surrounding the hair shaft in the upper right image (not adjusted, diagonal arrow).
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variations may include (1) tissue autofluorescence, (2)
nonspecific antibody binding, (3) tissue variations in nitro-
reductase activity, or (4) non-oxygen dependent metabolism
of drug. Data providing insight into these potential sources of
variation are discussed below:
Autofluorescence. We have found that the methods we use
do not produce tissue autofluorescence at wavelengths
appropriate for Cy3 (excitation¼ 541–551 nm and emis-
sion¼590LP nm; Nikon G-1B filter set). We tested for this
on all samples by imaging an unstained tissue section (data
not shown). One caveat is that surgical inks or tissues
containing tattoos can produce ultrabright spots of fluores-
cence that interfere with our quantitation techniques (see
Materials and Methods). Autofluorescence did increase at
lower excitation wavelengths, for example, those used for
Hoechst 33342 or FITC. This was not problematic for use of
Hoechst 33342 (UV excitation) to derive nuclear-DNA-based
tissue masks because the Hoechst-DNA emission was
uniformly bright.
Nonspecific antibody binding. Use of the anti-EF5 antibody
(ELK-51) produced only background levels of fluorescence in
tissues from patients who were not treated with EF5 (patients
no. 105 and 106; data not shown). It is impractical to obtain
biopsies from patients prior to EF5 administration, so we
devised an analytic method to provide the equivalent of
nonspecific antibody staining. This process is detailed in the
Materials and Methods section below. Briefly, a representa-
tive section from each patient was stained with the ELK 3-51
mixed with an excess of authentic EF5 drug (0.5 mM). The
excess drug binds to all specific sites on the antibody and
allows for only nonspecific binding. The fluorescence values
obtained from this control (termed ‘‘Competed Stain’’) were
about 100-fold less than the brightest binding areas of the
slides stained under standard conditions with noncompeted
ELK 3-51 antibody (‘‘Regular Stain’’). For data analysis, the
Competed Stain values were subtracted from the absolute
fluorescence values for the Regular Stain sections.
EF5 adducts formed under hypoxic conditions are
covalent and therefore stable over short periods of time.
However, they are eventually lost due to protein turnover.
One patient reported herein had skin studies performed
twice. This patient received EF5 preceding the first surgery
and skin was removed for analysis of EF5 binding. Additional
surgery in the head and neck region was required 5 months
later but EF5 was not administered at that time. As with
patients who had never received EF5 (patients no. 105, 106),
anti-EF5 binding not was observed in the second biopsy of
this patient.
Tissue variations in nitroreductase values. The dual purposes
of the CRB studies were to first determine whether the various
skin substructures (dermis, epidermis, hair follicles, seba-
ceous glands) had differing abilities to reduce and bind EF5
(due to differing nitroreductase levels) and second, to
determine the maximum binding levels possible for each
patient’s tissues. These CRB studies were performed with EF3.
EF3 and EF5 differ only in the number of sidechain fluorines
(3 or 5, respectively) and have essentially identical binding
characteristics when measured in vitro (Koch, 2001). We use
EF3 for the CRB studies because it is possible to distinguish
the EF5 adducts produced during the CRB in vitro study from
the EF5 in vivo binding by using antibodies specific for each
drug (EF5: Elk 3-51; EF3: Elk-A8).
Tissue was available for CRB studies in 10 patients (plus
two additional patients who did not receive EF5, Table 2b).
Eight patients had head and neck tumors and the skin tissue
was removed from the face/neck whereas in two patients with
lower extremity sarcomas, skin was removed from the thigh/
pelvis. Four patients (plus the two not receiving EF5) had CRB
studies performed on normal skin; five patients had CRB
Table 2a. Summary of in situ EF5 binding using absolute fluorescence
Patient ID no. Site
Absolute
CRB value Drug AUC
Average in situ
skin binding
67 H&N 612 1.47 408
79 H&N 1,916 1.20 13–92
85 H&N 687 1.45 73–78
91 Lower extremity 361 1.54 73
92 Lower extremity 308 1.63 68
93 (control) H&N 1,706 1.63 284
93 (irradiated) H&N 2,152 1.63 98
94 H&N 950 1.44 137–333
98 H&N 583 1.36 215–237
102 H&N 1,048 2.04 454
103 H&N 709 1.38 44
AUC, area under the curve; CRB, cube reference binding; H&N, head and neck.
Absolute CRB values are the average skin binding, corrected only for microscope exposure time and camera optics. To translate these absolute values into
tissue oxygen concentration, they must be corrected for drug AUC (in mM hours), and cube reference binding (CRB; see Tables 2c and d).
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studies performed on irradiated skin and one patient had both
irradiated and nonirradiated skin CRB studies performed. The
time interval between radiation and the EF5 study was 1 and
3 months for the patients having surgery in the pelvic/thigh
area, compared to 4, 8.5, and 10 months for the patients
having surgery in the head and neck region.
EF3 binding values from the CRB studies are reported on a
scale of absolute fluorescence. In all tissue cubes photo-
graphed and analyzed, a portion of the epidermis and dermis
was included. However, glandular tissue or hair follicles
were identified in only four tissue cubes from irradiated tissue
and three cubes from nonirradiated tissue. An example of an
‘‘optimal’’ CRB study is shown in Figure 3. This image shows
that cells throughout the skin bound EF3 at similar rates
(about a factor of 2 lower in the dermis). Despite the
consistent observation of similar maximal binding within the
various substructures of the skin in a cube from a single
patient, substantial differences in this end point were
observed between patients (Table 2b).
There was no significant difference in the overall CRB
values of irradiated (n¼ 7, average¼954, SD¼ 342) and
nonirradiated (n¼6, average¼1,045, SD¼ 732) skin tissues.
Whereas most of the tissues were from the head and neck
region, two samples of irradiated tissue were obtained from
patients with lower extremity sarcomas. The tissue samples
from the lower extremity had substantially lower CRB
compared to the tissues from the head/neck region
(average¼335, SD¼ 27 vs. average¼ 1,116, SD¼525,
respectively). While this difference is highly statistically
significant, there are too few samples from the lower
extremity for a valid conclusion at this time. Thus, inclusion
of the data from the two lower extremity samples caused a
much higher apparent range of CRB values (variation by a
factor o4 vs. 47 with their exclusion vs. inclusion,
respectively). This large difference between skin CRB in
patients with extremity sarcomas versus head and neck
tumors is discussed with respect to other patient variables,
below. However, since EF5 binding analysis on all skin
appendages were not available in all samples nor even in all
patients, a direct comparison of their means and standard
deviations cannot be made. The values are reported with this
caveat, in Table 2c.
Non-oxygen dependent metabolism of drug. While the CRB
results showed that maximum binding was similar among the
skin substructures of each patient, it was necessary to
demonstrate that this binding was hypoxia-dependent. Using
skin tissue from a patient who did not receive EF5, cubes
were incubated with EF5 in vitro using gas phase oxygen
concentrations of either 0.2 or 95% (Koch, 2001). For the
latter situation, binding was decreased more than 30-fold
(data not shown; image was completely black) compared
with the former, irrespective of skin substructure considered.
Therefore, all EF5 binding in skin appears to be hypoxia-
dependent.
EF5 binding is dependent not only on the inverse of
oxygen concentration but also on drug concentration multi-
plied by time. To account for drug concentration in the
calculation of in situ tissue binding, we measured EF5 in the
patient’s blood 1 hour after the drug was given and again
when the tumor was removed. It was then possible to
integrate the values of EF5 blood concentration over time to
calculate each patient’s EF5 drug exposure, known as the
area under the curve (AUC). As reported in the EF5 Phase I
trial (Koch et al., 2001), the drug AUC varies by about a total
factor of 2 for the patients described herein (Table 2a; range
Table 2b. Summary of cube reference binding
Whole cube Dermis Epidermis Hair follicle* Sebaceous gland*
Cube average value (SD) 996 (552) 596 (340) 1,148 (637) 798 (1,257) 389 (134)
% of average cube binding (SD) — 56 (11) 111 (6) 95 (31) 69 (14)
Cube min 308 136 302 206 225
Cube max 2152 1167 2290 2790 538
SD, standard deviation.
The CRB is expressed in absolute fluorescence values. Note that only dermis and epidermis were seen in all cubes. Thus, the values for the skin appendages
represent the average of only a subset of cubes*. The CRB range (cube max: cube min) is increased substantially by the low values seen for the extremity
samples of the sarcoma patients (no. 91 and no. 92).
a
b
Figure 3. Tissue cubes for calculation of CRB. (a) Brightest tissue section of
a tissue ‘‘cube’’ incubated in vitro under conditions of 0.2% pO2 in the
presence of EF3 (bar¼ 0.25 mm). (b) The corresponding Hoechst 33342
image, demonstrating the locations of nuclei. The fluorecence values
obtained from the analysis of (a) represent the maximum binding that this
specific tissue in this specific patient is capable of, for example, the CRB. CRB
is used as the denominator and in situ binding is used for the numerator in the
calculation of % maximum EF5 binding. We consistently found that dermis
CRB was lower (about two-fold) than in the other skin substructures, even
taking into account the lower cellular density in the dermis.
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1.2–2.4, average 1.2870.29 mMhours). Of course, drug AUC
only accounted for patient to patient variation and was
constant with the various skin substructures in an individual
patient.
Accounting for CRB and AUC, the corrected relative
intensities for the various skin substructures are summarized
in Table 2d. These data show that dermal oxygen levels were
consistently in the physiological range while those of the
epidermis ranged from physiological (oxic) to moderately
hypoxic (Table 2d). Oxygen levels for both sebaceous glands
and hair follicles varied from modest to severe hypoxia. EF5
binding values and gradients were consistent with the pattern
of blood vessels (anti-CD31 antibodies) and proliferating cells
(anti-Ki67 antibodies), which were located primarily in the
dermis (Figure 4).
Similarities in the rates of in situ binding between skin
substructures within the same patient suggest minimal intra-
patient variability in tissue nitroreductase activity. Conversely,
the substantial differences in the rates of in situ binding
between patients suggest that these variations were related to
corresponding differences in nitroreductase levels. We
considered several factors including site of tissue collection,
patient age and gender that might explain such differences.
The site of tissue collection (CRB in skin from head/neck
region4skin from lower extremity) was the only factor that
was associated with the CRB value. Therefore, we also
analyzed the relationship between the absolute values of CRB
of tumor tissue versus the CRB of skin removed at the surgery
site. The specific question being posed was whether each
patient had a characteristic ‘‘whole body’’ nitroreductase
activity, irrespective of tissue site. A statistically significant
correlation was found between the tumor and skin CRB
(Figure 5). These data support the hypothesis that each patient
may have a ‘‘characteristic’’ level of cellular nitroreductases.
Note that the two lowest values in this graph represent the two
skin tissue samples from patients with extremity sarcomas.
Owing to the small patient numbers, we do not know the
heterogeneity, etiology, or significance of the differences in
CRB values/nitroreductase levels between patients with
sarcomas versus head and neck cancer. Further insight will
only come from enrolling more patients in these studies.
DISCUSSION
Despite many years of study, considerable uncertainty
regarding the level(s) of skin oxygenation has remained.
Evidence from rodent studies supports the presence of skin
hypoxia because its radiation response could be increased by
drugs known to act as oxygen-mimetic radiosensitizers
(Stewart et al., 1982; Rojas et al., 1992; Stevens et al.,
1995). Most attempts to confirm this finding were based upon
the binding of prototypic hypoxia-binding drugs such as
misonidazole. (Cobb et al., 1989, 1990b, c) found a correla-
tion between misonidazole retention in stratified squamous
epithelia and elevated oxygen-independent reductase levels.
They concluded that misonidazole binding in skin and other
normal tissues (e.g. esophagus) was more likely due to high
reductase levels rather than the presence of hypoxia.
In contrast, Parliament et al. (1992) found that binding of
misonidazole to mouse esophageal mucosa was substantially
inhibited when animals breathed 100% oxygen. Unfortu-
nately, in the absence of a system to calibrate misonidazole
binding, the question of whether the murine esophageal
mucosa was hypoxic, and to what degree, remained unclear.
It is important to note that ‘‘nitroreductases’’ are not enzymes
whose function is to reduce nitro-compounds. Rather, they
are enzymes that functionally reduce such drugs, and their
actual identity is uncertain. EF5 was originally developed as
an alternative to misonidazole because misonidazole was
found to have a wide variation and poor characterization of
Table 2d. Relationship of EF5 binding and tissue pO2
Description PO2 (%)
PO2
(mm Hg)
% Maximal
binding (CRB)
Physiologic PO2 10 76 1
Modest hypoxia 2.5 19 3
Moderate hypoxia 0.5 3.8 10
Severe hypoxia 0.1 0.76 30
Anoxia 0.0 0.0 100
CRB, cube reference binding; PO2, oxygen partial pressure.
In this table, terms used to describe tissue oxygenation have been
approximated by data from in vitro experiments (Koch, 2001).
Table 2c. Summary of in situ EF5 values corrected for CRB
CF95 values for skin and its appendages
Dermis Epidermis Hair follicle Sebaceous gland
In situ average value (SD) 0.2 (0.4) 6.9 (4.7) 27.5 (13.9) 13.6 (13.1)
In situ minimum 0.00 1.2 6.0 4.0
In situ maximum 1.4 17.7 46.0 38.9
Term to explain ranges of tissue pO2 Physiologic pO2 Physiologic to moderate hypoxia Modest to severe hypoxia Modest to severe hypoxia
CF, cumulative frequency; CRB, cube reference binding; SD, standard deviation; PO2, oxygen partial pressure.
The value provided (CF95) is defined such that 95% of the image pixels exist at or below the stated percentage of maximal binding (corrected for all
parameters). In cases where a CRB value was not available from the same patient, an average value was used. Using the average relationship between EF5
binding and pO2 determined in in vitro studies (Table 2d) and assuming that the same relationship holds for human skin, one can assign oxygen ranges to the
skin and its appendages. Thus, oxygen levels in the dermis are consistently in the physiological range, while those of the epidermis range from physiological
to moderately hypoxic. Oxygen levels for both sebaceous glands and hair follicles vary from modest to severe hypoxia.
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its effective nitroreductase levels (Franko et al., 1987).
Misonidazole has also been found to have both oxygen-
dependent and oxygen-independent modes of metabolism
(Koch et al., 1993). Although comparative tests have shown
no oxygen-independent metabolism of EF5 (Koch, 1990), our
CRB data showed that nitroreductase activities vary substan-
tially between patients, even with EF5. There are no data as to
whether this might be true for inbred rodents. However, in
the case of humans, it emphasizes the need to consider an
individual patient’s characteristics.
Our ability to use EF5 to measure skin oxygenation in
patients undergoing tumor surgery provides a unique
opportunity to apply calibrated and validated methods
previously applied to tumors and some normal tissues
(Shapiro et al., 1997; Clyman et al., 1999). Our data provide
a consistent explanation for (1) the known radiation
sensitivity of skin, since most dividing cells were found in
regions with the least EF5 binding and (2) previous radiation
sensitizer data, since portions of skin certainly exist at oxygen
levels below venous pO2 (B6% oxygen). This may be of
substantial importance since hypoxia inhibits cell division
and skin stem cells in the hair follicle outer root sheath bulb
do not divide unless stimulated (Tumbar et al., 2004).
Our studies also showed the presence of moderate to very
high binding in some portions of human epidermis, seba-
ceous glands and hair follicles. These data partially agree
with prior murine skin studies using tritiated misonidazole
binding (Cobb et al., 1990c), with the major difference being
the frequency and heterogeneity of binding in human skin. In
view of patient-to-patient and tissue-to-tissue variability in
CRB, it is easy to understand the previous conclusion that
such binding was an artifact of nitroreductase level variation.
The difficulty with prior studies is that calibration studies on
the rates of hypoxia binding were not calculated in individual
patients or animals.
In human skin where the scale of substructures is larger,
we can explain EF5 binding gradients by true tissue pO2
gradients, supported by the distribution of blood vessels and
proliferating cells. The presence and extent of these gradients
are well documented in the cancer literature because of the
importance of hypoxia in tumor resistance to therapy. The
most common type of hypoxia gradient seen in tumors is
diffusion-limited, which is the same as the gradients we see in
skin. Our extensive studies of EF5 in cells and in tumors
demonstrate that these gradients are oxygen dependent
(Koch, 2001) and are not due to variations in nitroimidazole
activity. Nevertheless, the heterogeneity and rarity of such
gradients in skin beg the question of their etiology. While the
very general finding of moderately high binding in the
epidermis can be explained by oxygen diffusion from dermal
blood vessels, the occasional high binding in hair follicles
and sebaceous glands likely reflects local perturbations in
oxygen demand. Oxygen delivery to the epidermis has
previously been considered to arise from the dual planes of
the skin surface (air) and dermis (blood vessels). Therefore, it
is unexpected that the maximal in situ binding occurred in
a b
Figure 4. Co-localization of EF5 with proliferation and blood vessels. Images of skin from one patient presented to show the relationship between EF5 binding
(red) and blood vessels (CD31; green (a)) or proliferating cells (Ki67; green (b)). In both panels, nuclei are counter-stained with Hoescht 33342 (blue;
bar¼ 0.25 mm). The distribution of blood vessels supports the conclusion that the hypoxic regions are due to diffusion-limited oxygen metabolism since
the spatial relationship between blood vessels and hypoxia is inverse. Furthermore, the distance between hypoxic regions and blood vessels is compatible
with the range of oxygen diffusion suggested by Thomlinson and Gray (1955) (150–300 m). Note that the proliferating cells (b) are in physiologically oxic
to modestly hypoxic regions, explaining the sensitivity of these cells to radiation.
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Figure 5. Relationship between CRB (absolute values) in tumor tissue versus
overlying skin from each of eight patients (r2¼0.7, Po0.01). These data
were generated in order to determine whether the interpatient variation
seen for CRB in skin would also apply to an unrelated tissue (tumor) from the
same patient (i.e. does each patient have a characteristic nitroreductase
activity?). The highly significant relationship found suggests that this question
might be answered in the affirmative. However, the two lowest values are
from patients with extremity sarcomas; hence, their skin samples were
also taken from these anatomic sites, compared with most other values
from the head and neck region. Owing to the small patient numbers,
further insight into this question can only come from the accrual of
more patients.
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the most superficial level of viable epidermal cells. Several
explanations can be proposed. This may reflect relatively low
oxygen supply from the air, or there may be oxygen
consumption in the cornified layers and these cells could
be without nitroreductase activity. Since EF5 binding is a
metabolic process, one also has to consider the temperature
profile throughout the tissue. Another possibility is that the
oxygen diffusion constant may be different between sub-
regions of the epidermis and dermis. These possibilities must
be tested in further studies.
We have no means to measure the CRB of the individual
hair follicles and sebaceous glands with high in situ binding,
and we cannot formally exclude localized variations in
nitroreductase activity. However, we can provide an estimate
of the magnitude of such variations, since in situ EF5 binding
is measured on an absolute fluorescence scale. The absolute
EF5-derived fluorescence in high binding follicles, sebaceous
glands and epidermis is 20- to 50-fold higher than in other
low-fluorescence regions. It is very unlikely that such
variations represent local variations in nitroreductase activity
particularly since the high-binding areas are consistently
found at a distance from the nearest blood vessels.
Additionally, the absolute values in situ are not out of the
range (i.e. not greater than) predicted by the CRB. For similar
tissue appendages throughout the cube, we have not yet seen
heterogeneous local variations in binding.
Considerable controversy remains regarding nitroimida-
zole binding in squamous cell-containing tissues. ‘‘Non-
physiologic binding’’ has been reported in squamous cell
tumors removed from patients who received the hypoxia-
detection marker pimonidazole (Janssen et al., 2004). These
tissues were stained with both anti-pimonidazole antibodies
and nitro-blue tetrazolium, which is reduced by ‘‘nitro-
reductases’’ to a blue color. Pimonidazole staining was seen
in 56% of keratinized areas and of these, 78% showed
increased nitro-blue tetrazolium staining. These values
indicated that high reductase levels were not always required
for pimonidazole staining. However, it may not be the case
that the same enzymes involved in reduction of pimonida-
zole are involved in the reduction of nitro-blue tetrazolium
(Cobb et al., 1990a; Janssen et al., 2004). Certainly, one
could not conclude that the oxygen dependent kinetics of
such enzymes is independent of the drug used.
We have taken a different approach to examine whether
EF5 binding in keratinized regions of the skin is oxygen-
dependent. Rather than trying to assess the reductases
by using an alternative and uncharacterized agent such as
nitro-blue tetrazolium, we have used the binding of our
well-validated oxygen markers EF5 or EF3 as the indicators.
Our approach, previously reported with tumor tissues (Evans
et al., 2000, 2001a, 2004a, 2006), allows us to probe the
ability of the specific tissue and its associated enzymes to
reduce EF5, even if the exact enzyme is not known. To
summarize these ‘‘calibration’’ studies, internal variations in
nitroreductase activity, as exemplified by the CRB data,
suggest the presence of only a small tissue-to-tissue difference
for an individual patient, with dermis being about two-fold
less than epidermis and its appendages. We can conclude
that the large differences in in situ skin binding must be
directly caused by substantial oxygen gradients.
Our data do not support the presence of radiation-induced
hypoxia in skin. However the number of patients studied was
small and there was substantial heterogeneity regarding the
radiation doses received and the time between radiation
therapy and tissue examination. The questions of whether
hypoxia is a consequence of irradiation is still debated in the
literature (Denham and Hauer-Jensen, 2002). Rudolph et al.
(1994) reported the absence of ischemic lesions in irradiated
skin and observed that transcutaneous pO2 remained normal
in a series of 100 patients affected by radiation-induced
skin damage. Similarly, Aitasalo and Aro (1986) reported
only a transient change in oxygenation after radiation in a
rabbit model.
Hypoxia has been reported to be important in tissue
biology and pathology. Hypoxia is a well-described factor
in both radiation (Brown and Lemmon, 1991) and chemo-
therapy resistance (Adams, 1981). In the last decade,
molecular signaling via the HIF pathway has received a great
deal of attention regarding hypoxia’s role in tumor aggression
(Brahimi-Horn et al., 2001). Of particular relevance to the
skin is the recent observation that the presumed hypoxic
microenvironment of the skin could contribute to Akt-
mediated melanocyte transformation and may mediate the
development of melanomas (Bedogni et al., 2005). Tissue
pO2 is intimately involved with non-neoplastic tissue
pathologies such as stroke and myocardial infarction (Acker
and Acker, 2004) as well as mediating normal tissue repair
and wound healing (Hunt et al., 2004; Tandara and Mustoe,
2004). These processes have also been associated with
oxygen-related signaling cascades such as the generation of
reactive oxygen species and/or nitric oxide (e.g. see Rodrigo
et al., 2005). Oxygen levels are also thought to maintain
normal function in tissues such as the retina (Yu and Cringle,
2005). Thus, the work presented herein is of very general
interest since EF5 will measure hypoxia of almost any
etiology and in any tissue type. As emphasized in this paper,
however, in order to quantitatively evaluate tissue pO2
several specific control studies must be performed.
We conclude that the skin dermis is well-oxygenated and
associated with the presence of numerous blood vessels.
Proliferating cells are in these regions; their damage by
radiation explains acute radiation ‘‘dermatitis’’. In contrast,
substructures of the human skin may contain regions of
hypoxia; the etiology of the location and patterns of these
regions, as well as their biologic and clinical significance
requires further study. The techniques described for analyzing
EF5 binding are generally applicable to almost all tissue
systems.
MATERIALS AND METHODS
Human subjects
This study was conducted according to the Declaration of Helsinki
Principles. Written informed consent, approved by the University of
Pennsylvania Institutional Review Board which reviews ethical
issues, Clinical Trials and Scientific Monitoring Committee of the
University of Pennsylvania Cancer Center, Cancer Therapeutics
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Evaluation Program and the National Cancer Institute was obtained
from all patients entered on this study.
EF5 studies
Drug administration: The National Cancer Institute, Division of
Cancer Treatment (National Cancer Institute/DCT) supplied EF5 in
100 ml vials containing 3 mg/ml EF5 in water with 2.4% alcohol and
5% dextrose. Based on a previously conducted Phase I trial, the drug
solution was administered intravenously via a peripheral catheter at
a rate of approximately 350 ml/hours to a total dose of 21 mg/kg
(Koch et al., 2001). Eight to 10 ml of blood was collected in a
heparin tube preceding drug injection 1 hour after the start of drug
injection and at the time of surgery. The EF5 content was determined
in plasma using HPLC, as previously reported (Koch et al., 2001).
Based on these values, the drug AUC was calculated for each
patient. As EF5 binding is inversely proportional to tissue pO2 and
directly proportional to drug exposure levels, it is important that
tissue EF5 binding values be corrected for the AUC (Koch et al.,
2001; Evans et al., 2006).
Tissue acquisition, staining, photography, and analysis: Approxi-
mately 24 hours following completion of drug administration, the
patient was taken to surgery. The skin tissue studied herein was
removed as part of the procedure required for tumor resection and/or
reconstructive surgery. In patients where surgery included incision
into previously irradiated tissue, irradiated skin was sampled and
studied. In one patient, it was possible to collect both unirradiated
and irradiated skin. Skin tissue was also obtained from two patients
who did not receive EF5 preoperatively but were under going tumor
excision (negative control). Tumor tissue was collected in all
patients.
Skin tissue from each patient was frozen for analysis of in situ EF5
binding. Whenever possible, the skin was oriented during freezing to
ensure that a cross-section of the entire skin could be obtained.
Frozen sections (10 mm thickness) were cut using a Microm HM 505
cryostat (Carl Zeiss, MICROM Laborgera¨te GmbH, Waldorf,
Germany) then fixed, blocked and stained with Cy3-conjugated
anti-EF5 antibodies (ELK3-51 produced in-house), as previously
reported for tumors (Evans et al., 2004a). This staining sample is
referred to as the ‘‘Regular Stain’’. A representative section from each
patient was also stained with the standard anti-EF5 antibody mixed
with an excess of authentic EF5 drug, 0.5 mM. This control is termed
‘‘Competed Stain’’. The excess drug binds to all specific sites on the
antibody and prevents specific binding to tissue adducts. The
Competed Stain values were subtracted from the absolute fluores-
cence values for the Regular Stain sections. A no-stain control was
also performed.
Following staining, sections were stored at 41C in phosphate-
buffered saline containing 1% paraformaldehyde, a condition that
stabilizes the antibodies and prevents fluorescence loss (Koch,
2001). Images of the sections were made using a cooled CCD
camera and Nikon LabPhot fluorescence microscope (Nikon
Instrument Group, Inc., Melville, NY, USA) as described previously
(Evans et al., 2004a). This system generates images where
fluorescence can be assessed on an absolute scale by accounting
for the microscope’s lamp intensity and camera exposure time
(Koch, 2001). Since EF5 binding is also directly proportional to
drug concentration and time, the fluorescent signal obtained from
the tissue sections was normalized for the patient’s drug AUC
(Koch et al., 2001). The AUC is determined from HPLC analysis of
plasma EF5 concentration at the time of drug injection and at the
time of surgery (Koch et al., 2001). We have previously shown that
the fluorescence signal is a direct measure of absolute EF5 binding
(Koch, 2001).
Finally, to directly compare binding from one tissue to the next,
corrections must be made for the inherent EF5 metabolic rate. We
have shown that the oxygen dependence of EF5 binding is consistent
among many cell types in vitro, even though the absolute binding
level may vary. With the knowledge of the maximum binding rate
that the tissue is capable of, it is possible to determine the in situ
binding of the tissue on a pixel-by-pixel basis. Maximum binding,
rather than minimum, is determined in order to optimize accuracy at
low oxygen levels. The maximum binding rate is referred to as CRB
and is described below (Koch, 2001; Evans et al., 2004a). Thus, the
end points for EF5 binding presented herein reflects both the level
and proportional area of binding (Laughlin et al., 1996; Wilson et al.,
2000; Evans et al., 2004a).
Data were summarized by providing a cumulative frequency
analysis of all pixels in an image. Selected points on the cumulative
frequency curve were denoted by CF##. Thus, CF95¼ 20 means that
95% of the EF5 values in the image were at or below 20% of the
CRB. Following this nomenclature, median EF5 binding is denoted
as CF50 (Evans et al., 2004a). We have previously described our
procedure to produce oxygen maps from the EF5 binding images
(Koch, 2001; Evans et al., 2004a). The accurate generation of such
oxygen maps requires that the oxygen dependence of EF5 binding is
known. Based on current data for tumor, fibroblast and other cell
lines, we have defined several ranges of tissue pO2 and their
approximate equivalents of percent maximum EF5 binding (Koch,
2001). Thus, the qualitative terms physiological, modest hypoxia,
moderate hypoxia, severe hypoxia, and anoxia have been assigned
average oxygen partial pressures as summarized in Table 2d.
In about half of the patients studied, sufficient skin tissue was
available to determine CRB, as well as in situ binding (Koch, 2001;
Evans et al., 2004a). Briefly, for CRB determination, 2 mm skin cubes
were cut from the main tissue sample with surgical blades. Each
cube had the epidermis intact. These cubes were incubated under
hypoxic conditions (0.2% oxygen) with 200 mM EF3 (a drug closely
related to EF5) for 3 hours. The EF5 dose/time interval was chosen to
approximate that of the in situ tissue exposure. The tissue cubes were
incubated at 0.2% oxygen rather than 0% oxygen in order to
minimize binding in the damaged cells at the edge of the cube (due
to artifacts of cutting the cube). We count on tissue respiration to
allow the maximum binding at close to 0% pO2 to be a few cell
layers inside the cube surface. Depending upon the cell density
(which is low in the dermis), tissue damage or variations in the
distance of the cells of interest to the surface of the ‘‘cube’’, there can
be substantial variations in binding, but we only consider its
regionally maximal value.
Cubes were frozen, sectioned on the cryostat (10 m), stained with
the appropriate monoclonal antibody and imaged. EF3 and EF5 have
essentially equivalent binding characteristics (Koch, 2001). Owing
to the difference in their sidechain structure, it is possible to stain the
tissue cubes with a distinct Cy3-conjugated antibody, Elk5-A8, with
little interference from EF5 adducts that may be present from the
in situ binding (Koch et al., 1995; Busch et al., 2000). Since there
was heterogeneity of cell types and cell densities in skin, subanalyses
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of the in situ EF5 binding and in vitro EF3 binding (CRB) were
performed. Analysis of the level of EF5 binding in each photo-
micrograph was performed by identifying each of the anatomic
substructures present in each section: dermis, epidermis, sebaceous
glands, and hair follicles. It should be noted that not every section
contained all structures (a particular problem for the limited tissue
available from cubes). Calculation of the absolute binding (cubes) or
CF95 (in situ tissues) was then performed on each region of each
tissue section. In order to analyze all areas, a tissue mask was made
by counterstaining sections with Hoechst 33342 to identify nuclei.
This image was then translated in MATLAB into the tissue mask
(Evans et al., 2004a). This method successfully eliminates acellular
areas such as hair shafts and sebaceous secretions. However, this
masking process may slightly underestimate the degree of dermis
binding, which has a substantially lower cell density than epidermis
and appendages (no binding would be expected, nor was any found,
in extracellular matrix or other acellular regions). A subset of tissue
sections was also stained for Ki67 (proliferation) and/or CD31 (blood
vessels) as previously reported (Evans et al., 2001b).
Histopathological analyses
The anatomic correlation of the EF5 binding regions was made by
counterstaining the EF5-stained slides with hematoxalin and eosin.
A subset of hematoxalin and eosin slides was reviewed by the
pathologist (PZ) to identify the characteristics of sebaceous glands
and hair follicles. This information was then applied to analyses on
the other tissue sections.
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